These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Good L; Benner B; Carson WE Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636 [TBL] [Abstract][Full Text] [Related]
5. The role of Bruton's tyrosine kinase in the immune system and disease. McDonald C; Xanthopoulos C; Kostareli E Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359 [TBL] [Abstract][Full Text] [Related]
6. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development. Liu J; Chen C; Wang D; Zhang J; Zhang T Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells. Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547 [TBL] [Abstract][Full Text] [Related]
9. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996 [TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125 [TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823 [TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711 [TBL] [Abstract][Full Text] [Related]
15. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors. Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181 [TBL] [Abstract][Full Text] [Related]
16. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy. Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103 [TBL] [Abstract][Full Text] [Related]
17. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. Geethakumari PR; Awan F Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675 [TBL] [Abstract][Full Text] [Related]
19. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis. Pery N; Rizvi NB; Shafiq MI J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204 [TBL] [Abstract][Full Text] [Related]
20. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase. Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]